Issue Date | Title | Author(s) |
2018-02-01 | Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30 | King, MT; Viney, R; Simon Pickard, A; Rowen, D; Aaronson, NK; Brazier, JE; Cella, D; Costa, DSJ; Fayers, PM; Kemmler, G; McTaggart-Cowen, H; Mercieca-Bebber, R; Peacock, S; Street, DJ; Young, TA; Norman, R; Aaronson, N; Brazier, J; Costa, D; Fayers, P; Grimison, P; Janda, M; King (Chair), M; McTaggart-Cowan, H; Pickard, S; Velikova, G; Street, D; Young, T |
2019 | Developing UK values for cancer health states | Norman, R; Mercieca-Bebber, R; Brazier, JE; Cella, D; Pickard, AS; Rowen, D; Street, D; Viney, R; King, MT |
2018-11-05 | Efficacy of Anamorelin, a novel non-peptide ghrelin analogue, in patients with advanced non-small cell lung cancer (NSCLC) and Cachexia—Review and expert opinion | Currow, DC; Maddocks, M; Cella, D; Muscaritoli, M |
2017-08-01 | Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format (Quality of Life Research, (2016), 25, 3, (637-649), 10.1007/s11136-015-1115-3) | Norman, R; Viney, R; Aaronson, NK; Brazier, JE; Cella, D; Costa, DSJ; Fayers, PM; Kemmler, G; Peacock, S; Pickard, AS; Rowen, D; Street, DJ; Velikova, G; Young, TA; King, MT |
2018-12 | Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study | Cella, D; McKendrick, J; Kudlac, A; Palumbo, A; Oukessou, A; Vij, R; Zyczynski, T; Davis, C |
2021-06-01 | The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set | King, MT; Norman, R; Mercieca-Bebber, R; Costa, DSJ; McTaggart-Cowan, H; Peacock, S; Janda, M; Muller, F; Viney, R; Pickard, AS; Cella, D |
2021-06 | The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. | King, MT; Norman, R; Mercieca-Bebber, R; Costa, DSJ; McTaggart-Cowan, H; Peacock, S; Janda, M; Müller, F; Viney, R; Pickard, AS; Cella, D; Multi-Attribute Utility in Cancer Consortium, |
2019 | U.K. utility weights for the EORTC QLU‐C10D | Norman, R; Mercieca-Bebber, R; Rowen, D; Brazier, JE; Cella, D; Pickard, AS; Street, DJ; Viney, R; King, MT |
2024-01 | United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument. | King, MT; Revicki, DA; Norman, R; Müller, F; Viney, RC; Pickard, AS; Cella, D; Shaw, JW; MAUCa Consortium, |
2016-03-01 | Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format | Norman, R; Viney, R; Aaronson, NK; Brazier, JE; Cella, D; Costa, DSJ; Fayers, PM; Kemmler, G; Peacock, S; Pickard, AS; Rowen, D; Street, DJ; Velikova, G; Young, TA; King, MT |